SkinBioTherapeutics (LON:SBTX) Trading 9.4% Higher

SkinBioTherapeutics Plc (LON:SBTXGet Rating) traded up 9.4% during mid-day trading on Monday . The company traded as high as GBX 18.33 ($0.22) and last traded at GBX 17.50 ($0.21). 543,110 shares changed hands during trading, an increase of 120% from the average session volume of 246,688 shares. The stock had previously closed at GBX 16 ($0.20).

SkinBioTherapeutics Stock Performance

The business’s fifty day moving average price is GBX 18.88 and its 200-day moving average price is GBX 20.81. The company has a debt-to-equity ratio of 3.07, a quick ratio of 10.01 and a current ratio of 11.19. The stock has a market cap of £28.63 million and a PE ratio of -15.22.

SkinBioTherapeutics Company Profile

(Get Rating)

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health. It develops SkinBiotix technology that can enhance the formation of multi-protein complexes and prevent passage toxins, molecules, and ions, as well as pathogens; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.

Featured Stories

Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.